Table 2.

Serum concentrations of 25OHD3, 25OHD2, 3-epi-25OHD3, and 24,25(OH)₂D3 in 5 human serum samples under different hydrolysis conditions

	25OHD3 (ng/mL)			25OHD2 (ng/mL)
Serum	No enzyme	Beta-glucuronidase	PVFV-PaS	No enzyme	Beta-glucuronidase	PVFV-PaS
S1	31.1 (64.1%)	31.4 (0.6%)	48.2 (35.3%)	0.351 (72.2%)	0.389 (7.8%)	0.448 (20.0%)
S2	20.9 (53.7%)	22.2 (3.3%)	37.6 (42.9%)	0.460 (63.2%)	0.486 (3.6%)	0.702 (33.2%)
S3	12.7 (65.1%)	13.1 (2.1%)	19.1 (32.8%)	0.588 (76.2%)	0.594 (0.8%)	0.766 (23.1%)
S4	23.5 (48.0%)	26.2 (5.5%)	46.3 (46.5%)	0.310 (74.7%)	0.314 (1.0%)	0.411 (24.3%)
S5	34.1 (55.7%)	36.3 (3.6%)	59.0 (40.7%)	0.783 (54.4%)	0.853 (4.9%)	1.370 (40.8%)
Mean	24.5 ± 8.5 (57.3 ± 7.3%)	25.8 ± 8.9 (3.0 ± 1.8%)	42.0 ± 14.9 (39.6 ± 5.6%)	0.498 ± 0.192 (68.1 ± 9.2%)	0.527 ± 0.210 (3.6 ± 2.9%)	0.739 ± 0.385 (28.3 ± 8.6%)
	3-Epi-25OHD3 (ng/mL)			24,25(OH)2D3 (ng/mL)
Serum	No enzyme	Beta-glucuronidase	PVFV-PaS	No enzyme	Beta-glucuronidase	PVFV-PaS
S1	1.74 (66.4%)	2.11 (14.4%)	2.25 (19.5%)	1.47 (46.1%)	1.51 (1.3%)	3.15 (57.2%)
S2	1.48 (68.8%)	1.74 (12.1%)	1.89 (19.1%)	1.76 (38.3%)	1.82 (1.3%)	4.54 (60.4%)
S3	0.62 (63.3%)	0.77 (15.3%)	0.83 (21.4%)	0.83 (55.3%)	0.89 (4.0%)	1.44 (40.7%)
S4	1.47 (77.8%)	1.57 (5.3%)	1.79 (16.9%)	2.07 (41.2%)	2.33 (5.2%)	4.76 (53.6%)
S5	2.11 (77.3%)	2.33 (8.1%)	2.51 (14.7%)	2.34 (41.0%)	2.43 (1.6%)	5.62 (57.4%)
Mean	1.48 ± 0.55 (70.7 ± 6.5%)	1.70 ± 0.60 (11.0 ± 4.2%)	1.85 ± 0.64 (18.3 ± 2.6%)	1.69 ± 0.58 (44.4 ± 6.7%)	1.80 ± 0.63 (2.7 ± 1.8%)	3.90 ± 1.64 (53.0 ± 7.5%)

Sample measurements were performed without hydrolysis (No enzyme) or with either PVFV-PaS or beta-glucuronidase. The percentage of unconjugated and conjugated forms in each sample is shown in brackets; unconjugated % (no enzyme), glucuronide % (beta-glucuronidase), and sulfate % (PVFV-PaS).